title: Randomized placebo-controlled trial of pantoprazole for daytime sleepiness in GERD and obstructive sleep disordered breathing.
abstract: OBJECTIVE
  To determine the efficacy of pantoprazole therapy for daytime somnolence, psychomotor vigilance, and quality of life in patients with mild-moderate obstructive sleep disordered breathing (OSDB) and gastroesophageal reflux disease (GERD).
  
  
  METHODS
  Randomized, double-blind, placebo-controlled crossover trial.
  
  
  METHODS
  Sixty patients with daytime sleepiness, mild-moderate OSDB and GERD were randomly assigned a 2-week treatment with pantoprazole 40 mg or placebo followed by a 2-week washout period and crossover respectively to 2-week treatment with placebo or pantoprazole. Outcomes included Epworth Sleepiness Score (ESS), sleep-related quality-of-life (FOSQ), and reaction time.
  
  
  RESULTS
  With pantoprazole, patients reported statistically significantly greater improvement of overall reflux symptoms (P = 0.0003) and in ESS (P = 0.04). A significant improvement was noted in FOSQ for both treatments with a trend toward greater improvement with pantoprazole (P = 0.058). No improvement in reaction times was observed.
  
  
  CONCLUSIONS
  Patients with coexistent GERD and OSDB noted significant improvement in daytime sleepiness after treatment with pantoprazole over placebo likely related to a reduction in nocturnal reflux-related arousals.
authors.affiliation: Department of Otolaryngology, Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, OH 45267-0528, USA. Maria.Suurna@uc.edu <Maria.Suurna@uc.edu>
authors.forename: Maria V
authors.initials: MV
authors.lastname: Suurna
authors.forename: Jeff
authors.initials: J
authors.lastname: Welge
authors.forename: Victoria
authors.initials: V
authors.lastname: Surdulescu
authors.forename: Jonathan
authors.initials: J
authors.lastname: Kushner
authors.forename: David L
authors.initials: DL
authors.lastname: Steward
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001143:Arousal / Q000187:drug effects; D018592:Cross-Over Studies; D006970:Disorders of Excessive Somnolence / Q000188:drug therapy* / Q000209:etiology; D004311:Double-Blind Method; D005260:Female; D005764:Gastroesophageal Reflux / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077402:Pantoprazole; D010919:Placebos; D011788:Quality of Life; D012891:Sleep Apnea Syndromes / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome; D014851:Wakefulness / Q000187:drug effects
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D010919:Placebos; D000077402:Pantoprazole